Adding MTX to Pegloticase for 52 wks in gout ◦ Improved response rate by 30% ◦ Reduced discontinuation rate by 40% ◦ Greater resolution of tophi by 20% ◦ Similar safety profile in MTX vs non-MTX groups Botson J, MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow https://t.co/le9ggUa2Xk

• 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicen…

Abs 0412 by @Spondy_MD et al at #ACR22: BKZ tx showed meaningful improvements in physical function and HRQoL in nr-axSpA and AS pts with consistent responses. @RheumNow https://t.co/diGqpQKfpS https://t.co/1pdGi47IJM

• Bimekizumab Improves Physical Function and Health-Related Quality of Life in Pa…

Can we use sputum to identify progression to RA in at-risk individuals? Sputum anti-CCP-IgA anti-CCP-IgG & RF-IgM positivity = 4-fold increase risk of classified RA in IgG CCP+ at-risk individuals. Sens 67% Spe 80% https://t.co/o6PCvxgYGM Abs #0533 #ACR22 #ACRBest @Rheumnow https://t.co/CxDjanjBKT

• Sputum RA-Associated Autoantibodies Independently Associate with Future Develop…

What’s new to treat PsA? Let’s discuss anti-IL-17A, Izokibep #ACR22 @RheumNow Abstract #0199 💪 Izokibep 40 v. 80 mg q2 weeks SQ v. placebo 💪 135 patients, 28 sites 💪 At 12 weeks, all patient reported outcomes and PsAID subdomains significantly improved (dose dependent)

Another study showing treatment withdrawal does not work. Golimumab withdrawal in nr-axSpA is inferior to continued treatment or tapered treatment, leading to more disease flares. Abs#0545 @RheumNow #ACR22 https://t.co/CBRnVdxXVo

2022 ASAS-EULAR recommendation lit review in Abs 0413 at #ACR22 shows new evidence on education & exercise and confirms efficacy in axSpA. Tofa, UPA, FIL have shown efficacy in r-axSpA. @RheumNow https://t.co/8E9RZQ8Gz4 https://t.co/5QPO5eddFH

• Efficacy and Safety of Non-Pharmacological and Non-Biological Therapy: A System…

Interesting findings from Abs 0417 - when early axSpA is defined by duration of symptoms, only nr-axSpA tx w/ bDMARDs may lead to better outcomes vs early or established axSpA. #ACR22 @RheumNow https://t.co/8aGdyJRvv1 https://t.co/chAEGPicPd

• Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Lit…

NSAIDs plus TNFi (celecoxib and golimumab) therapy in ankylosing spondylitis did not show significant decrease in radiographic progression compared to TNFi monotherapy. *Numerical reduction in syndesmophytes 11% vs. 25% Abs#0546 @RheumNow #ACR22 #ACRBest https://t.co/pG5F3xdsh9

Abs 0419 SELECT-AXIS 2, UPA improved outcomes vs PBO in nr-axSpA pts across all BL inflammation subgroups; greatest benefit obs in pts with both elevated CRP and inflammation on baseline MRI. #ACR22 @RheumNow https://t.co/opaFwXgcvU https://t.co/o27ULcL8Ip

• Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthri…

In GCA, do you give pulse IV methylpred to patients with visual symptoms (instead of ongoing oral pred)? #ACR22 @RheumNow

#Abstr 0545 GO-BACK Trial Continue vs Withdrawal of GOL in nr-axSpA with inactive disease - Full tx withdrawal associated w/ dx flare - Re-treatment -->rapid clinical response after flare - qMonthly tx --> higher rates of disease activity improvement @RheumNow #ACR22 https://t.co/Z3bhA9D4RQ

P hoc analysis by Dr AGomez et al fr 4 Ph3 RCTs of BEL in #lupus investigated predictors of renal flares 📌Adjusted:⬇️c3, plasma alb & proteinuria levels at BL 📌Non-adj: antidsDNA+, antiSm+ addt'l predictors 🧐p alb & antiSm+ potential predictors? #ACR22 @RheumNow ABST#540 https://t.co/EYcD7pDYQe

Majority of pts withdrawn from IXE to PBO recaptured at least LDA & over half met ID w/ IXE retreatment. This may help us clinically with pts who have treatment interruptions. Abs 0427 #ACR22 @RheumNow https://t.co/m4c3P8l25m https://t.co/iQshG1oq2Y

• Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Ax…

The CONSUL trial by Dr Proft et al. compared impact of CEL+GOL vs. GOL alone on radiographic spinal progression in AS showed no significant difference bet. the 2 grps in mSASSS change after 108 wks. Risk stratify pts who will benefit from tx #ACR22 @RheumNow ABST#0546 #ACRBest https://t.co/jWwX7w85ur

Clinical pearl! First-line tx w/ bio-originator or biosimilar ADA/ETA showed similar effectiveness & safety in long-term cohort of axSpA pts. Response to treatment was also similar between groups. Abs 0431 #ACR22 @RheumNow https://t.co/bGGXk51hIG https://t.co/PSsX3MpSXt

• Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar…